Patient Center

Myovant Sciences is dedicated to developing innovative new products to treat diseases specific to women, including uterine fibroids, endometriosis and female infertility, as well as to develop novel treatments for prostate cancer and other hormone-driven diseases.



Uterine Fibroids

Uterine fibroids are non-cancerous tumors that develop from the muscle and connective tissue of the uterus. Approximately 25% of women of reproductive age have uterine fibroids, and 1 in 4 experience symptoms requiring treatment. Although uterine fibroids are benign tumors, they may cause debilitating symptoms including heavy and prolonged menstrual bleeding, anemia, and pelvic pain. Current treatments include hormonal contraceptives, GnRH agonists, and surgical interventions including myomectomy and hysterectomy.
Endometriosis is a gynecological medical condition in which cells that normally line the uterus grow outside of the uterine cavity. An estimated 7.5 million women in the United States have endometriosis, and 3 in 4 experience symptoms requiring treatment. During the menstrual cycle, endometriosis lesions grow, differentiate and shed into the abdomen, causing symptoms including non-menstrual pelvic pain and pain during menstruation (dysmenorrhea). Current treatments include hormonal contraceptives, danazol, GnRH agonists, and various surgical interventions for severe cases.


Prostate Cancer

Prostate cancer is a malignant transformation of tissue within the male prostate gland. Often characterized by slow growth, prostate cancer is the second most prevalent form of cancer in men and the second leading cause of death due to cancer in men in the United States. Approximately 2.9 million men in the United States are currently living with prostate cancer, and 180,000 men are newly diagnosed each year. Symptoms of prostate cancer include increased urinary frequency, dysuria, hematuria and nocturnal urination. Current treatments include combinations of surgery, radiation or proton beam therapy, androgen deprivation therapy, and chemotherapy.
Approximately 25% of infertile women have problems related to ovulation, including the inability to produce fully matured eggs or release an egg from the ovary (i.e., "ovulate"). Fertility specialists use a group of medications, including GnRH agonists, to temporarily correct ovulatory problems and increase a woman's chance for pregnancy. These and related procedures are broadly termed Assisted Reproductive Technology, or ART. Approximately 1.5 million cycles of ART were performed globally in 2012.

Female Infertility



  • Nakata, D., Masaki, T., Tanaka, A., Yoshimatsu, M., Akinaga, Y., Asada, M.,…Kusaka, M. (2014). Suppression of the hypothalamic–pituitary–gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock-in mice. European Journal of Pharmacology, 723, 167-174.

  • MacLean, D. B., Shi, H., Faessel, H. M., & Saad, F. (2015). Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. The Journal of Clinical Endocrinology & Metabolism, 100(12), 4579-4587.

  • AUA 2016 prostate cancer oral presentation by Dr. Neal D. Shore (April 2016). Testosterone Lowering, PSA Response, and Quality of Life in Patients with Advanced Hormone-Sensitive Prostate Cancer Receiving TAK-385, an Oral GnRH Antagonist: Phase 2 Interim Analysis.

  • ASCO GU 2016 prostate cancer poster presentation by Fred Saad. Second interim analysis results from a phase 2 trial of TAK-385, an oral GnRH antagonist, in patients with prostate cancer.

Add-Back Therapy

  • Lee, D., Park, H. G., Yoon, B., & Choi, D. (2016). Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis. Obstetrics & Gynecology Science, 59(1), 32.

  • Barbieri, R. L. (1992). Hormone Treatment of Endometriosis. Obstetrical & Gynecological Survey, 47(9), 645-646.

  • Divasta, A. D., & Laufer, M. R. (2013). The use of gonadotropin releasing hormone analogues in adolescent and young patients with endometriosis. Current Opinion in Obstetrics and Gynecology, 25(4), 287-292.

  • Chwalisz, K., Surrey, E., & Stanczyk, F. Z. (2012). The Hormonal Profile of Norethindrone Acetate: Rationale for Add-Back Therapy with Gonadotropin-Releasing Hormone Agonists in Women With Endometriosis. Reproductive Sciences, 19(6), 563-571.

  • Wu, D., Hu, M., Hong, L., Hong, S., Ding, W., Min, J.,…Guo, W. (2014). Clinical efficacy of add-back therapy in treatment of endometriosis: A meta-analysis. Archives of Gynecology and Obstetrics, 290(3), 513-523.


  • MacLean, D. B., Matsui, H., Suri, A., Neuwirth, R., & Colombel, M. (2014). Sustained Exposure to the Investigational Kisspeptin Analog, TAK-448, Down-Regulates Testosterone into the Castration Range in Healthy Males and in Patients With Prostate Cancer: Results From Two Phase 1 Studies. The Journal of Clinical Endocrinology & Metabolism, 99(8).

  • Abbara, A., Jayasena, C. N., Christopoulos, G., Narayanaswamy, S., Izzi-Engbeaya, C., Nijher, G. M.,…Dhillo, W. S. (2015). Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. The Journal of Clinical Endocrinology & Metabolism, 100(9), 3322-3331.